Biogen: Sclerosis trials

The registry lists 137 Sclerosis studies with Biogen as lead sponsor. 0 are open to participants now and 49 have results posted.

Phase 1 9Phase 2 20Phase 3 36Phase 4 31No phase 43(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)CompletedNCT01185717
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)CompletedNCT01181115Phase 3
• Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT01181089Phase 1/2
• Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological SurveillanceTerminatedNCT01156298
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabCompletedNCT01070836
• JC-Virus (JCV) Antibody ProgramCompletedNCT01070823
• Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex SyringeCompletedNCT00915577Phase 3
• Open-Label Safety Extension Study of AvonexCompletedNCT00915460Phase 4
• Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy VolunteersCompletedNCT00913666Phase 4
• A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy VolunteersCompletedNCT00913250Phase 1
• Immunogenicity and Safety Study of Serum-Free AvonexCompletedNCT00912860Phase 2
• Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSCompletedNCT00884481
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSCompletedNCT00837785Phase 1
• A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder FunctionCompletedNCT00818038
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady StateCompletedNCT00744679Phase 4
• Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple SclerosisCompletedNCT00599274
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
• Avonex 15 Year Long Term Follow-up StudyCompletedNCT00525343
• Tysabri Observational ProgramCompletedNCT00493298
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
• Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta TherapyCompletedNCT00493077Phase 4
• Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT00492765Phase 4
• GER-009-06-AVX Early Therapy in Multiple SclerosisCompletedNCT00492570
• Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
• TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of WorldCompletedNCT00483847
• TYSABRI Global Observational Program in SafetyCompletedNCT00477113
• A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple SclerosisCompletedNCT00288990
• Open-Label Natalizumab Safety Extension StudyCompletedNCT00276172Phase 3
• Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
• Efficacy and Safety of BG00012 in MSCompletedNCT00168701Phase 2
• AVONEX® Combination Trial - "ACT"CompletedNCT00112034Phase 4
• Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisCompletedNCT00030966Phase 3
• Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisCompletedNCT00027300Phase 3